期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 120, 期 9, 页码 3099-3102出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI44312
关键词
-
资金
- NIAID NIH HHS [R01 AI044374, AI44374, AI45459, R01 AI035370, AI35370, R01 AI045459] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035370, R01AI045459, R01AI044374] Funding Source: NIH RePORTER
The appearance of methicillin-resistant Staphylococcus aureus (MRSA) as an endemic microbe, first in hospital and health care settings and more recently in the community, has led to a disastrous situation in which use of the available antibiotic armamentarium is increasingly ineffective and spawns further antibiotic resistance. This vicious cycle highlights the pressing need for an S. aureus vaccine. However, to date, clinical trials with S. aureus vaccines have not demonstrated sustained efficacy. In this issue of the JCI, Skurnik and colleagues report that specific antibodies to two different S. aureus surface polysaccharides, which independently promote effector cell killing of S. aureus in vitro and protection against S. aureus in animal models, bind to and abrogate the activity of one another when they are combined. This fascinating finding suggests a new paradigm to explain the failure of antibody immunity to S. aureus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据